Shan Liang, Wang Fengling, Zhai Dandan, Meng Xiangyun, Liu Jianjun, Lv Xiongwen
Department of Pharmacy, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, Anhui, 230011, China.
Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, Anhui, 230032, China.
J Inflamm Res. 2024 Jul 23;17:4905-4920. doi: 10.2147/JIR.S432024. eCollection 2024.
Biliary atresia (BA) is a severe neonatal progressive cholangiopathy of unknown etiology. A timely Kasai portoenterostomy (KPE) improves survival of the native liver in patients with BA, although liver transplantation remains the ultimate treatment for most (60%-80%) patients. However, postoperative adverse effects of liver transplantation may be significant. In addition, patients require lifelong immunosuppressive therapy after liver transplantation.
Here, we report a case of a newborn female baby (birthday: 10-03-2018) with congenital BA (confirmed at 76 days of life) who survived KPE (first surgery at 85 days of life) and underwent successful living-related liver transplantation (LRLT) (second surgery at 194 days of life). Additionally, we reviewed the existing literature on BA. After KPE (at 85 days of life), the liver function of the baby did not improve, and the indicators of liver and kidney function showed a trend of aggravation, indicating that the liver function had been seriously damaged before KPE (at 85 days of life), demonstrating the urgent need for liver transplantation surgery. The female baby survived after part of her father's liver was successfully transplanted into her body (at 194 days of life). The patient recovered successfully. No other diseases were found at the 4-year follow-up, and all indices of liver and kidney functions tended to be normal.
This case highlights the following. Postoperative alkaline phosphatase was consistently above the normal range, although the reason for this was unclear; neither tacrolimus nor cyclosporine A has formulations designed specifically for infants, which does not meet the needs of clinical individualized medication, suggesting that these anti-rejection drugs are future development directions. Only one case of congenital BA has been found thus far in Hefei, and this case has extremely important reference significance for the prevention, treatment, and diagnosis of BA in Hefei, Anhui province.
胆道闭锁(BA)是一种病因不明的严重新生儿进行性胆管病。及时进行Kasai肝门空肠吻合术(KPE)可提高BA患者天然肝脏的存活率,尽管肝移植仍是大多数(60%-80%)患者的最终治疗方法。然而,肝移植的术后不良反应可能很严重。此外,患者在肝移植后需要终身免疫抑制治疗。
在此,我们报告一例先天性BA(出生76天时确诊)的新生女婴(出生日期:2018年3月10日),该患儿KPE手术存活(出生85天时首次手术)并成功接受了活体亲属肝移植(LRLT)(出生194天时第二次手术)。此外,我们回顾了关于BA的现有文献。KPE术后(出生85天时),患儿肝功能未改善,肝肾功能指标呈加重趋势,表明KPE术前(出生85天时)肝功能已严重受损,显示出迫切需要进行肝移植手术。该女婴在成功接受其父亲部分肝脏移植到体内后存活(出生194天时)。患者成功康复。4年随访未发现其他疾病,肝肾功能各项指标趋于正常。
本病例突出了以下几点。术后碱性磷酸酶一直高于正常范围,尽管原因尚不清楚;他克莫司和环孢素A均没有专门为婴儿设计的剂型,不符合临床个体化用药需求,提示这些抗排斥药物是未来的发展方向。迄今为止,合肥仅发现1例先天性BA病例,该病例对安徽省合肥市BA的预防、治疗及诊断具有极其重要的参考意义。